VERMONT

Department of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda

March 28, 2023: 6:00 – 8:30 p.m.

- **Executive Session**   **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes**   **6:30 - 6:35**
  (Public Comment Prior to Board Action**)**

- **DVHA Pharmacy Administration Updates**   **6:40 - 6:45**
  - Open board positions: the DUR Board is seeking physician and mid-level practitioners.

- **Chief Medical Officer Updates**   **6:45 - 6:50**

- **Follow-up Items from Previous Meetings**   **6:50 – 6:50**

- **RetroDUR/ProDUR**   **6:50- 7:20**
  - Data presentation: Concurrent use of Opioids and Antipsychotics
  - Introduce: Adherence to Heart Failure Medications

- **Clinical Update: Drug Reviews**   **7:20-7:40**
  (Public comment prior to Board action)

  Biosimilar Drug Reviews
  - None at this time.

  Full New Drug Reviews
  (Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)

  - Sotyktu® (deucravacitinib)
  - Spevigo® (spesolimab-sbzo)

- **New Managed Therapeutic Drug Classes**   **7:40 -7:50**
  - Potassium Reducing Agents

  (Public comment prior to Board action)
  - None at this time

- **Therapeutic Drug Classes – Periodic Review**   **7:50 - 8:20**

(Public comment prior to Board action)
- Angiotensin Modulators & Heart Failure & Other Cardiovascular Agents (new drug Camzyos® (mavacamten) included)
- Beta Blockers, Anti-Anginals, & Sinus Node Agents (new drug Aspruzyo® (ranolazine) included)
- Calcium Channel Blockers (new drug Norliqva® (amlodipine) and Levamlodipine included)
- Anti-migraine: Triptans and CGRP Antagonist
- Bile Salts & Biliary Agents
- Botulinum Toxins
- Lipotropics: Statins
- Lipotropics: Other (Non-Statins)

- **Review of Newly Developed/Revised Criteria**   **8:20 - 8:25**
  (Public comment prior to Board action)
    - Miscellaneous ADHD and Narcolepsy Cataplexy Medications

- **General Announcements**   **8:25 – 8:30**
    - None at this time.

- **Adjourn**   **8:30**